Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in GBA1, the gene encoding lysosomal glucocerebrosidase, are the most frequent known genetic risk factor for Parkinson's disease. Reduced glucocerebrosidase and α-synuclein accumulation are directly related in cell models of Parkinson's disease. We investigated relationships between Parkinson's disease-specific glucocerebrosidase deficits, glucocerebrosidase-related pathways, and α-synuclein levels in brain tissue from subjects with sporadic Parkinson's disease without GBA1 mutations. Brain regions with and without a Parkinson's disease-related increase in α-synuclein levels were assessed in autopsy samples from subjects with sporadic Parkinson's disease (n = 19) and age- and post-mortem delay-matched controls (n = 10). Levels of glucocerebrosidase, α-synuclein and related lysosomal and autophagic proteins were assessed by western blotting. Glucocerebrosidase enzyme activity was measured using a fluorimetric assay, and glucocerebrosidase and α-synuclein messenger RNA expression determined by quantitative polymerase chain reaction. Related sphingolipids were analysed by mass spectrometry. Multivariate statistical analyses were performed to identify differences between disease groups and regions, with non-parametric correlations used to identify relationships between variables. Glucocerebrosidase protein levels and enzyme activity were selectively reduced in the early stages of Parkinson's disease in regions with increased α-synuclein levels although limited inclusion formation, whereas GBA1 messenger RNA expression was non-selectively reduced in Parkinson's disease. The selective loss of lysosomal glucocerebrosidase was directly related to reduced lysosomal chaperone-mediated autophagy, increased α-synuclein and decreased ceramide. Glucocerebrosidase deficits in sporadic Parkinson's disease are related to the abnormal accumulation of α-synuclein and are associated with substantial alterations in lysosomal chaperone-mediated autophagy pathways and lipid metabolism. Our data suggest that the early selective Parkinson's disease changes are likely a result of the redistribution of cellular membrane proteins leading to a chronic reduction in lysosome function in brain regions vulnerable to Parkinson's disease pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, loss‐of‐function mutations in GBA disrupt the autophagic flux and lead to the aggregation of SNCA/α‐synuclein (Murphy et al, 2014).”
From Autophagy in major human diseases (2021) · cites this paper as Murphy et al, 2014
Citations
Cites
1 retracted
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
How to Interpret LC3 Immunoblotting
Mizushima, N., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4600 · Cited by 2,669
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Lysosomal membrane permeabilization in cell death
Boya, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.310 · Cited by 1,426
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citation
Research works printed but not linked: 1
- Stone, 2000, Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease, Hum Mutat, 15, 181, 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S · DOI · Paper page
Cited by
Items 101–200 of 475
Kumaran, R., & Cookson, M. R. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv236 · Cited by 86
“GBA is also associated with increased intracellular α-synuclein as observed in the brains of idiopathic PD individuals (127).”
BackgroundPang, S. Y.-Y., Lo, R., Ho, P. W., Liu, H., Chang, E. E. S., Leung, C.-T., Malki, Y., Choi, Z. Y.-K., Wong, W. Y., Kung, M. H.-W., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00281-6 · Cited by 92
“A study on postmortem brain samples of early-stage iPD patients has shown reduced GCase activity selectively in brain regions that accumulate α-syn [16].”
BackgroundMeng, Y., Pople, C. B., Huang, Y., Jones, R. M., Ottoy, J., Goubran, M., de Oliveira, L. M., Davidson, B., Lawrence, L., Lau, A. Z., et al. (2022) · Movement Disorders · doi:10.1002/mds.29190 · Cited by 97
“GCase deficit can be present in the brains of patients with either GBA1-related PD or idiopathic PD(10-12) and is associated with disease severity and PD pathology.(12-14) Taken together, GCase replacement may be a promising approach for disease modification in PD.”
Backgroundɑ‐Synuclein strains and the variable pathologies of synucleinopathies
Peelaerts, W., & Baekelandt, V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13595 · Cited by 105
Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery
Arotçarena, M.-L., Teil, M., & Dehay, B. (2019) · Cells · doi:10.3390/cells8060565 · Cited by 97
“Its decreased activity was found to correlate with an increased α-syn amount at the early stages of the disease [55].”
BackgroundProteotoxicity and Neurodegenerative Diseases
Ruz, C., Alcantud, J. L., Montero, F. V., Durán, R., & Bandrés‐Ciga, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165646 · Cited by 89
Mitochondrial lipids in neurodegeneration
Aufschnaiter, A., Kohler, V., Diessl, J., Peselj, C., Carmona-Gutierrez, D., Keller, W., & Büttner, S. (2017) · Cell and Tissue Research · doi:10.1007/s00441-016-2463-1 · Cited by 83
“Loss of this enzyme results in a drop of ceramide levels, reduced autophagy and high levels of α-synuclein (Murphy et al. 2014).”
BackgroundBoutin, M., Sun, Y., Shacka, J. J., & Auray‐Blais, C. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04227 · Cited by 92
Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations
Abeliovich, A., Hefti, F. F., & Sevigny, J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212739 · Cited by 102
Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Teil, M., Arotçarena, M.-L., Faggiani, E., Laferrière, F., Bézard, E., & Dehay, B. (2020) · Biomolecules · doi:10.3390/biom10030391 · Cited by 86
Uemura, N., Koike, M., Ansai, S., Kinoshita, M., Ishikawa‐Fujiwara, T., Matsui, H., Naruse, K., Sakamoto, N., Uchiyama, Y., Todo, T., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005065 · Cited by 88
Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease
Пчелина, С. Н., Emelyanov, A., Baydakova, G., Andoskin, P. A., Senkevich, K. A., Nikolaev, M. A., Miliukhina, I. V., Yakimovskii, А. F., Timofeeva, A., Fedotova, E. Y., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.039 · Cited by 87
Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function
Kim, M. J., Jeon, S., Burbulla, L. F., & Krainc, D. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy105 · Cited by 81
Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease
Pitcairn, C., Wani, W. Y., & Mazzulli, J. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.008 · Cited by 75
Insights into the structural biology of Gaucher disease
Smith, L., Mullin, S., & Schapira, A. H. V. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.09.010 · Cited by 87
Sardi, S. P., Cheng, S. H., & Shihabuddin, L. S. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.12.001 · Cited by 80
Alpha galactosidase A activity in Parkinson's disease
Alcalay, R. N., Wolf, P., Levy, O. A., Kang, U. J., Waters, C., Fahn, S., Ford, B., Kuo, S., Vanegas, N., Shah, H., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.012 · Cited by 81
Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism
Tayebi, N., Lopez, G. J., Do, J., & Sidransky, E. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.004 · Cited by 77
Self-citationParkinson's disease: acid‐glucocerebrosidase activity and alpha‐synuclein clearance
Blanz, J., & Saftig, P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13517 · Cited by 71
Smolders, S., & Broeckhoven, C. V. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00935-4 · Cited by 75
Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments
Gegg, M. E., Menozzi, E., & Schapira, A. H. V. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105663 · Cited by 83
“It should also be noted that GBA variants increase the risk of developing dementia with Lewy bodies (DLB) with odds ratio greater than for PD (Bras et al., 2014; Nalls et al., 2013).”
BackgroundAutophagy Modulation as a Treatment of Amyloid Diseases
Mputhia, Z., Hone, E., Tripathi, T., Sargeant, T. J., Martins, R. N., & Bharadwaj, P. (2019) · Molecules · doi:10.3390/molecules24183372 · Cited by 70
Menozzi, E., Toffoli, M., & Schapira, A. H. V. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108419 · Cited by 74
Gündner, A. L., Durán-Pacheco, G., Zimmermann, S., Ruf, I., Moors, T. E., Baumann, K., Jagasia, R., van de Berg, W. D. J., & Kremer, T. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.015 · Cited by 80
Kurzawa-Akanbi, M., Tammireddy, S., Fabrik, I., Gliaudelytė, L., Doherty, M. K., Heap, R., Matečko-Burmann, I., Burmann, B. M., Trost, M., Lucocq, J. M., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02367-3 · Cited by 69
Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients
Papagiannakis, N., Xilouri, M., Koros, C., Stamelou, M., Antonelou, R. C., Maniati, M., Papadimitriou, D. A., Moraitou, M., Michelakakis, H., & Stefanis, L. (2015) · Movement Disorders · doi:10.1002/mds.26433 · Cited by 74
“Recent reports reveal that reduced GCase protein level and enzymatic activity are associated with a-Syn accumulation in affected brain regions of PD patients.(12,18) Whether such lysosomal alterations are reflected in peripheral PD tissues remains unknown.”
BackgroundLieberman, O. J., Choi, S. J., Kanter, E., Saverchenko, A., Frier, M. D., Fiore, G. M., Wu, M., Kondapalli, J., Zampese, E., Surmeier, D. J., et al. (2017) · eneuro · doi:10.1523/eneuro.0167-17.2017 · Cited by 69
“, 1997), its increased expression and phosphorylation in postmortem brains of sporadic PD patients (Fujiwara et al., 2002; Anderson et al., 2006; Murphy et al., 2014) and an autoimmune response to the protein in PD patients (Sulzer et al.”
BackgroundYang, S., Beavan, M. S., Chau, K., Taanman, J., & Schapira, A. H. V. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.011 · Cited by 76
Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease
Han, T., Sam, R., & Sidransky, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00271 · Cited by 74
Self-citationXilouri, M., & Stefanis, L. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.01.003 · Cited by 72
Clark, L. N., Chan, R., Cheng, R., Liu, X., Park, N., Parmalee, N., Kisselev, S., Cortes, E., Torres, P. A., Pastores, G. M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125204 · Cited by 67
“A decrease in GCase activity has also been reported in brain autopsies from patients with sporadic PD without GBAmutations, with the greatest reduction in the substantia nigra [29] and conflicting reports of decreased GCase activity in the frontal cortical regions [29, 30].”
BackgroundCeramide Metabolism and Parkinson’s Disease—Therapeutic Targets
Custodia, A., Aramburu-Núñez, M., Correa‐Paz, C., Posado-Fernández, A., Gómez-Larrauri, A., Castillo, J., Gómez‐Muñoz, A., Sobrino, T., & Ouro, A. (2021) · Biomolecules · doi:10.3390/biom11070945 · Cited by 64
Zarkali, A., McColgan, P., Ryten, M., Reynolds, R., Leyland, L.-A., Lees, A. J., Rees, G., & Weil, R. S. (2020) · Brain · doi:10.1093/brain/awaa270 · Cited by 64
“Mutations in GBA are associated with a higher risk of Parkinson’s disease whilst even in sporadic Parkinson’s dis- ease glucocerebrosidase activity is significantly decreased, with associated impaired lysosomal chaperone-mediated authophagy (Murphy et al., 2014).”
BackgroundXing, Y., Tang, Y., Zhao, L., Wang, Q., Qin, W., Ji, X., Zhang, J., & Jia, J. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.09.028 · Cited by 63
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Zhang, X., Wu, H., Tang, B., & Guo, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00437-6 · Cited by 71
“Studies conducted on human samples have revealed a negative correlation between pathological α-syn and GCase activity in brain tissues of PD patients and a negative correlation between GCase activity in leucocytes and plasma oligomeric α-syn in patients with GD [123, 127, 128].”
BackgroundCongdon, E. E., Lin, Y., Rajamohamedsait, H. B., Shamir, D. B., Krishnaswamy, S., Rajamohamedsait, W. J., Rasool, S., Gonzalez, V., Levenga, J., Gu, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0126-z · Cited by 63
Ceramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
Plotegher, N., Bubacco, L., Greggio, E., & Civiero, L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00330 · Cited by 71
Chaperone mediated autophagy in aging: Starve to prosper
Xilouri, M., & Stefanis, L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.07.001 · Cited by 77
Flores‐León, M., & Outeiro, T. F. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02601-0 · Cited by 70
A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease
Omer, N., Giladi, N., Gurevich, T., Bar‐Shira, A., Gana‐Weisz, M., Goldstein, O., Kestenbaum, M., Cedarbaum, J. M., Orr‐Urtreger, A., Mirelman, A., et al. (2020) · Movement Disorders · doi:10.1002/mds.28066 · Cited by 60
Systems biology approaches to study lipidomes in health and disease
Alves, M. A., Lamichhane, S., Dickens, A. M., McGlinchey, A. J., Ribeiro, H. C., Sen, P., Wei, F., Hyötyläinen, T., & Orešič, M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158857 · Cited by 65
Liu, G., Chen, M., Mi, N., Yang, W., Li, X., Wang, P., Yin, N., Li, Y., Yue, F., Chan, P., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.004 · Cited by 60
“Although the above evidence suggests an interaction betweenGCase anda-syn in PD patients with GBA mutations, a recent study has also found a negative correlation between GCase activity and a-syn levels in PD patients without these mutations, suggesting that the interaction is present even in sporadic PD (Murphy et al.…”
BackgroundMethodInfluentialLRRK2 deficiency impacts ceramide metabolism in brain
Ferrazza, R., Cogo, S., Melrose, H., Bubacco, L., Greggio, E., Guella, G., Civiero, L., & Plotegher, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.082 · Cited by 60
Recent progress in the role of autophagy in neurological diseases
Meng, T., Lin, S., Zhuang, H., Huang, H., He, Z., Hu, Y., Gong, Q., & Feng, D. (2019) · Cell Stress · doi:10.15698/cst2019.05.186 · Cited by 58
Advances in GBA-associated Parkinson's disease – Pathology, presentation and therapies
Barkhuizen, M., Anderson, D. G., & Grobler, A. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.12.004 · Cited by 68
“This is likely due to differences in PD staging and the accumulation of α- M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT synuclein in the frontal cortex at the time of examination (Murphy et al., 2014).”
InfluentialGlucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons
Gegg, M. E., Verona, G., & Schapira, A. H. V. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa085 · Cited by 66
“Increased WT or mutant α -syn levels have been reported to decrease GCase activity and protein levels in cell and animal models and human brain (6, 7, 10, 19).”
GBA-associated PD: chances and obstacles for targeted treatment strategies
Höglinger, G. U., Schulte, C., Jost, W. H., Storch, A., Woitalla, D., Krüger, R., Falkenburger, B. H., & Brockmann, K. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02511-7 · Cited by 62
Pyszko, J., & Strosznajder, J. B. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.45567 · Cited by 64
“It was found that reduced glucocerebrosidase and, in consequence, accumulation of glucosylceramide are associated with an increased ASN level in sporadic PD [34].”
BackgroundCeramide signalling in inherited and multifactorial brain metabolic diseases
Pant, D. C., Aguilera, S., & Pujol, A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105014 · Cited by 60
“An imbalance in ceramide levels is a common feature in PD mouse models and PD post-mortem brains (Abbott et al., 2014; Ferrazza et al., 2016; K. E. Murphy et al., 2014).”
BackgroundBehl, T., Madaan, P., Sehgal, A., Singh, S., Sharma, N., Bhatia, S., Al‐Harrasi, A., Chigurupati, S., Alrashdi, I., & BUNGAU, S. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810161 · Cited by 63
Blennow, K., Biscetti, L., Eusebi, P., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26656 · Cited by 66
“Interestingly, the reduction of GCase activity in PD brains is paralleled by neuronal accumulation of a-syn.(148,149) To this end, it is worth noting that glucosylceramide, the GCase substrate, stabilizes soluble oligomeric a-syn species.”
BackgroundStrong association between glucocerebrosidase mutations and Parkinson's disease in Sweden
Ran, C., Brodin, L., Forsgren, L., Westerlund, M., Ramezani, M., Gellhaar, S., Xiang, F., Fardell, C., Nissbrandt, H., Söderkvist, P., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.022 · Cited by 60
“…as compared with healthy controls, suggesting GBA is involved in the pathologic mechanisms of PD even in the absence of known GBA gene under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). mutations (Alcalay et al., 2015; Chiasserini et al., 2015; Murphy et al., 2014).”
BackgroundInfluentialComplement cascade functions during brain development and neurodegeneration
Fatoba, O., Itokazu, T., & Yamashita, T. (2021) · FEBS Journal · doi:10.1111/febs.15772 · Cited by 61
Avenali, M., Toffoli, M., Mullin, S., McNeill, A., Hughes, D. A., Mehta, A. B., Blandini, F., & Schapira, A. H. V. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320394 · Cited by 62
TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson’s disease
Seo, B. A., Kim, D., Hwang, H., Kim, M. S., Ma, S.-X., Kwon, S., Kweon, S. H., Wang, H., Yoo, J. M., Choi, S., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.09.031 · Cited by 57
Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease
Zhao, Y., & Dzamko, N. L. (2019) · Drugs · doi:10.1007/s40265-019-01139-4 · Cited by 58
Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson’s Disease
Bonam, S. R., Tranchant, C., & Muller, S. (2021) · Cells · doi:10.3390/cells10123547 · Cited by 57
Gaucher disease provides a unique window into Parkinson disease pathogenesis
Hertz, E., Chen, Y., & Sidransky, E. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00999-z · Cited by 68
“Several studies have shown lower levels of GCase even in people with PD who do not carry pathological variants in GBA1 , but a similar result has not been found consistently in all studies 126,176,177 .”
Self-citationNeurons and Glia Interplay in α-Synucleinopathies
Mavroeidi, P., & Xilouri, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094994 · Cited by 62
GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
Huh, Y. E., Usnich, T., Scherzer, C. R., Klein, C., & Chung, S. J. (2023) · Journal of Movement Disorders · doi:10.14802/jmd.23023 · Cited by 58
“91 This study found a negative correlation between β-glucocerebrosidase activity and α-synuclein levels in the anterior cingulate cortex.”
Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies
Dai, L., Liu, M., Ke, W., Chen, L., Fang, X., & Zhang, Z. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05419-5 · Cited by 61
Zhao, Y., Perera, G., Takahashi-Fujigasaki, J., Mash, D. C., Vonsattel, J. P. G., Uchino, A., Hasegawa, K., Jeremy Nichols, R., Holton, J. L., Murayama, S., et al. (2018) · Brain · doi:10.1093/brain/awx344 · Cited by 49
Self-citationNelson, M. P., Boutin, M., Tse, T. E., Lu, H., Haley, E., Ouyang, X., Zhang, J., Auray‐Blais, C., & Shacka, J. J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.11.006 · Cited by 52
“not observe significant changes in GCase activity in PD brain as compared to previously published reports (Gegg et al. 2012; Mazzulli et al. 2011; Murphy et al. 2014), the significant negative correlation observed between decreasing activity with increasing p129S-α-syn supports their relative association.”
InfluentialAutophagy and LRRK2 in the Aging Brain
Albanese, F., Novello, S., & Morari, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01352 · Cited by 55
“The relevance of this pathway is further strengthened by the finding that even PD patients without GBA1 mutations showed a reduced GCase activity in the same cerebral areas displaying α-syn deposition (Mazzulli et al., 2011; Murphy et al., 2014).”
BackgroundPapagiannakis, N., Koros, C., Stamelou, M., Simitsi, A., Maniati, M., Antonelou, R. C., Papadimitriou, D. A., Dermentzaki, G., Moraitou, M., Michelakakis, H., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.012 · Cited by 55
Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease
Paciotti, S., Albi, E., Parnetti, L., & Beccari, T. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020594 · Cited by 52
“found reduced GBA activity in the lysosomal-enriched protein fractions of early stage PD patients, more specifically in the anterior cingulated cortex [43].”
Backgroundβ-Glucocerebrosidase activity in GBA -linked Parkinson disease: The type of mutation matters
Huh, Y. E., Chiang, M. S. R., Locascio, J. J., Liao, Z., Liu, G., Choudhury, K., Kuras, Y. I., Tuncali, I., Videnović, A., Hunt, A. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009989 · Cited by 57
Muñoz, S. S., Petersen, D., Marlet, F. R., Kücükköse, E., & Galvagnion, C. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106534 · Cited by 53
Inhibition of nSMase2 Reduces the Transfer of Oligomeric α-Synuclein Irrespective of Hypoxia
Sackmann, V., Sinha, M. S., Sackmann, C., Civitelli, L., Bergström, J. J. E., Ansell, A., & Hallbeck, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00200 · Cited by 50
“As there have been conflicting results regarding sphingolipids in PD brains (Cheng et al., 2011; Fabelo and Martin, 2011; Abbott et al., 2014; Murphy et al., 2014; Gegg et al., 2015; Bienias et al., 2016), we wanted to investigate whether inhibiting nSMase2 affects the lipid composition of…”
BackgroundResultInfluentialPlasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
Surface, M., Balwani, M., Waters, C., Haimovich, A., Gan‐Or, Z., Marder, K. S., Hsieh, T., Song, L., Padmanabhan, S., Hsieh, F., et al. (2021) · Movement Disorders · doi:10.1002/mds.28846 · Cited by 52
Advances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson’s Disease
Xie, F., Gao, X., Yang, W., Chang, Z., Yang, X., Wei, X., Huang, Z., Xie, H., Yue, Z., Zhou, F., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00520 · Cited by 48
Yap, T. L., Jiang, Z., Heinrich, F., Gruschus, J. M., Pfefferkorn, C. M., Barros, M., Curtis, J. E., Sidransky, E., & Lee, J. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610584 · Cited by 52
Self-citationGenetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
Granek, Z., Barczuk, J., Siwecka, N., Rozpędek‐Kamińska, W., Kucharska, E., & Majsterek, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032044 · Cited by 51
“An inverse correlation between GCase activity and α-synuclein accumulation has been reported in GCase-deficient cells, fly and mouse models, as well as in GBA1-PD and sporadic PD brains [77,82,83].”
BackgroundThe autophagy-lysosomal pathway: General concepts and clinical implications
Kenney, D. L., & Benarroch, E. E. (2015) · Neurology · doi:10.1212/wnl.0000000000001860 · Cited by 45
“GBA mutations in sporadic PD are related to the early accumulation of a-SYN and dysregulation of chaperone-mediated autophagy pathways and lipid metabolism.(70) Whereas acid b-glucocerebrosidase alters a-SYN processing,(71,72) pharmacologic inhibition of the enzyme did not affect a-SYN clearance, oligomeric aggregatio…”
BackgroundSoria, F. N., Engeln, M., Martínez‐Vicente, M., Glangetas, C., López‐González, M. J., Doveró, S., Dehay, B., Normand, E., Vila, M., Favereaux, A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx120 · Cited by 50
“Furthermore, despite decreased GCase activity in PD brains (13,46) there is no substrate accumulation in brain homogenate of PD patients with GBA1 mutations (12).”
BackgroundDrobny, A., Boros, F. A., Balta, D., Huarcaya, S. P., Caylioglu, D., Qazi, N., Vandrey, J., Schneider, Y., Dobert, J. P., Pitcairn, C., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00363-z · Cited by 48
“For instance, the activity of GCase, an important lysosomal enzyme that hydrolyses glucosylceramide into glucose and ceramide [58], was found to be reduced in brain tissues of PD patients, including the SN [59, 60].”
BackgroundChaperone-Based Therapies for Disease Modification in Parkinson’s Disease
Friesen, E. L., de Snoo, M. L., Rajendran, L., Kalia, L. V., & Kalia, S. K. (2017) · Parkinson s Disease · doi:10.1155/2017/5015307 · Cited by 45
Lin, C., Wei, P., Chen, C., Huang, Y., Lin, J.-L., Lo, Y., Lin, J.-L., Lin, C., Wu, Y., Chang, K., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00226 · Cited by 49
Domínguez-Bautista, J. A., Klinkenberg, M., Brehm, N., Subramaniam, M., Kern, B., Roeper, J., Auburger, G. W. J., & Jendrach, M. (2015) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2015.01.003 · Cited by 54
The effect of mutant GBA1 on accumulation and aggregation of α-synuclein
Maor, G., Rapaport, D., & Horowitz, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz005 · Cited by 46
Vinueza‐Gavilanes, R., Íñigo-Marco, I., Larrea, L., Lasa, M., Carte, B., Santamaría, E., Fernández‐Irigoyen, J., Bugallo, R., Aragón, T., Aldabe, R., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104781 · Cited by 47
Zhang, J., Zhang, X., Wang, L., & Yang, C. (2017) · Medical Science Monitor · doi:10.12659/msm.904399 · Cited by 42
Khair, S. B. A., Dhanushkodi, N. R., Ardah, M. T., Chen, W., Yang, Y., & Haque, M. E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00081 · Cited by 41
“Decreased GCase activity has been reported in patients with or without GBA (Murphy and Halliday, 2014; Murphy et al., 2014; Aflaki et al., 2016) as there is an age-dependent reduction in GCase activity that may lower the threshold to develop PD in persons even in the absence of any genetic mutation in GBA gene.”
BackgroundMultimodal assessment of mitochondrial function in Parkinson's disease
Payne, T., Burgess, T., Bradley, S., Roscoe, S., Sassani, M., Dunning, M., Hernandez, D. G., Scholz, S. W., McNeill, A., Taylor, R. N., et al. (2023) · Brain · doi:10.1093/brain/awad364 · Cited by 48
Marotta, N., Kim, S., & Krainc, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1703671 · Cited by 42
Sun, Y., Liou, B., Chu, Z., Fannin, V., Blackwood, R., Peng, Y., Grabowski, G. A., Davis, H. W., & Qi, X. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102735 · Cited by 39
High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease
Klatt‐Schreiner, K., Valek, L., Kang, J., Khlebtovsky, A., Trautmann, S., Hahnefeld, L., Schreiber, Y., Gurke, R., Thomas, D., Wilken‐Schmitz, A., et al. (2020) · Movement Disorders · doi:10.1002/mds.28186 · Cited by 41
“From a mechanistic viewpoint, it is presently unknown how high levels of glucosylceramides affect sensory neurons, but there is strong evidence that low activity of the GlcCer-metabolizing enzyme GBA1 increases the toxicity of α-synuclein.(34,38,70-74) Importantly, low GBA1 activity has been observed in PD patients ca…”
BackgroundExploring the Role of Autophagy Dysfunction in Neurodegenerative Disorders
Rana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Bhatia, S., Al‐Harrasi, A., & BUNGAU, S. G. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02472-0 · Cited by 42
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
Omer, N., Giladi, N., Gurevich, T., Bar‐Shira, A., Gana‐Weisz, M., Glinka, T., Goldstein, O., Kestenbaum, M., Cedarbaum, J. M., Mabrouk, O. S., et al. (2021) · Movement Disorders · doi:10.1002/mds.28792 · Cited by 49
Leyns, C. E. G., Prigent, A., Beezhold, B., Yao, L., Hatcher, N. G., Tao, P., Kang, J. J., Suh, E. R., Deerlin, V. M. V., Trojanowski, J. Q., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00517-w · Cited by 42
Lipids: biomarkers of healthy aging
Almeida, I., Magalhães, S., & Nunes, A. (2021) · Biogerontology · doi:10.1007/s10522-021-09921-2 · Cited by 48
“Those gangliosides are metabolized by enzyme b-glucosidase (GCase), and the reduced GCase activity in the nervous system (Murphy et al. 2014) has been associated with PD (Papagiannakis et al. 2015; Kim et al. 2016), maybe because of the alteration in lipid metabolism by GCase (Chan et al. 2017).”
BackgroundChaperone-mediated autophagy as a therapeutic target for Parkinson disease
Campbell, P., Morris, H. R., & Schapira, A. H. V. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1517156 · Cited by 40
“Furthermore, the loss of GCase activity and increase in ɑ-synuclein were shown to be directly related to reduced LAMP2A levels in PD brains, suggesting impaired CMA [98].”
BackgroundAutophagic- and Lysosomal-Related Biomarkers for Parkinson’s Disease: Lights and Shadows
Xicoy, H., Peñuelas, N., Vila, M., & Laguna, A. (2019) · Cells · doi:10.3390/cells8111317 · Cited by 43
α-Synuclein aggregation and transmission in Parkinson’s disease: a link to mitochondria and lysosome
Wang, R., Sun, H., Ren, H., & Wang, G. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1756-9 · Cited by 38
GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders
Martínez‐Bailén, M., Clemente, F., Matassini, C., & Cardona, F. (2022) · Pharmaceuticals · doi:10.3390/ph15070823 · Cited by 37
“GCase mutations were shown to be a major risk factor of developing PD: approximately 7–12% of PD patients carry GBA mutations [96], and 25% of GD patients have a first- or second-degree relative with PD [97].”
BackgroundCan GBA1-Associated Parkinson Disease Be Modeled in the Mouse?
Farfel‐Becker, T., Do, J., Tayebi, N., & Sidransky, E. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.05.010 · Cited by 40
Self-citationVesicular Dysfunction and the Pathogenesis of Parkinson’s Disease: Clues From Genetic Studies
Ebanks, K., Lewis, P. A., & Bandopadhyay, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01381 · Cited by 36
Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset
Schierding, W. S., Farrow, S. L., Fadason, T., Graham, O. E. E., Pitcher, T. L., Qubisi, S., Davidson, A. J., Perry, J. K., Anderson, T., Kennedy, M. A., et al. (2020) · Movement Disorders · doi:10.1002/mds.28144 · Cited by 39
Self-citationCaminiti, S. P., Carli, G., Avenali, M., Blandini, F., & Perani, D. (2021) · Movement Disorders · doi:10.1002/mds.28818 · Cited by 37
Metadata
- Authors
- Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M.
- Affiliations
- UNSW Sydney (AU)
- Neuroscience Research Australia (AU)
- University of Wollongong (AU)
- National Institutes of Health (US)
- Garvan Institute of Medical Research (AU)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-28
- Volume
- 137
- Issue
- 3
- Pages
- 834-848
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3927701
- OpenAlex
- W2144140825
- Cited by
- 475
- References
- 85
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 37 · 2023: 31 · 2022: 39 · 2021: 52 · 2020: 54 · 2019: 49 · 2018: 30 · 2017: 34 · 2016: 42 · 2015: 42 · 2014: 15
- FWCI
- 29.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Figshare (submittedVersion, cc-by)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R24AA012725, R28AA012725)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, alpha-synuclein, GBA1, sporadic Parkinson's disease, lysosomal dysfunction, chaperone-mediated autophagy, ceramide, sphingolipids, early-stage Parkinson's disease, brain regions, inclusion formation
- MeSH terms
- Aged, Aged, 80 and over, Autophagy, Brain, Female, Glucosylceramidase, Humans, Lysosomes, Male, Mutation, Parkinson Disease, Cohort Studies, Up-Regulation, Case-Control Studies, Molecular Chaperones, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.